Acelrx (ACRX) Gets a Hold Rating from Jefferies


Jefferies analyst Matthew Andrews reiterated a Hold rating on Acelrx (NASDAQ: ACRX) today and set a price target of $3. The company’s shares opened today at $2.80.

According to TipRanks.com, Andrews is a 5-star analyst with an average return of 29.1% and a 45.7% success rate. Andrews covers the Healthcare sector, focusing on stocks such as Urogen Pharma Ltd, CTI BioPharma, and Sesen Bio Inc.

Acelrx has an analyst consensus of Moderate Buy, with a price target consensus of $5.33, a 90.4% upside from current levels. In a report issued on August 3, Oppenheimer also assigned a Hold rating to the stock.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $5.75 and a one-year low of $1.55. Currently, Acelrx has an average volume of 770.4K.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ACRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of acute pain. Its products include DSUVIA and ZALVISO. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.

Read More on ACRX:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts